Correlation Between CRISPR Therapeutics and Marvell Technology

Can any of the company-specific risk be diversified away by investing in both CRISPR Therapeutics and Marvell Technology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CRISPR Therapeutics and Marvell Technology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between CRISPR Therapeutics AG and Marvell Technology, you can compare the effects of market volatilities on CRISPR Therapeutics and Marvell Technology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CRISPR Therapeutics with a short position of Marvell Technology. Check out your portfolio center. Please also check ongoing floating volatility patterns of CRISPR Therapeutics and Marvell Technology.

Diversification Opportunities for CRISPR Therapeutics and Marvell Technology

0.32

Correlation Coefficient

CRISPR Therapeutics  Marvell Technology

Weak diversification

The 3 months correlation between CRISPR and Marvell is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding CRISPR Therapeutics AG and Marvell Technology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Marvell Technology and CRISPR Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CRISPR Therapeutics AG are associated (or correlated) with Marvell Technology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Marvell Technology has no effect on the direction of CRISPR Therapeutics i.e., CRISPR Therapeutics and Marvell Technology go up and down completely randomly.

Pair Corralation between CRISPR Therapeutics and Marvell Technology

Assuming the 90 days trading horizon CRISPR Therapeutics AG is expected to under-perform the Marvell Technology. But the stock apears to be less risky and, when comparing its historical volatility, CRISPR Therapeutics AG is 1.29 times less risky than Marvell Technology. The stock trades about -0.31 of its potential returns per unit of risk. The Marvell Technology is currently generating about 0.15 of returns per unit of risk over similar time horizon. If you would invest  6,600  in Marvell Technology on October 8, 2024 and sell it today you would earn a total of  708.00  from holding Marvell Technology or generate 10.73% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	94.12%
Values	Daily Returns

CRISPR Therapeutics AG  vs.  Marvell Technology

CRISPR Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in CRISPR Therapeutics AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Marvell Technology

Risk-Adjusted Performance

19 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Marvell Technology are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Marvell Technology sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with CRISPR Therapeutics and Marvell Technology

The main advantage of trading using opposite CRISPR Therapeutics and Marvell Technology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CRISPR Therapeutics position performs unexpectedly, Marvell Technology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marvell Technology will offset losses from the drop in Marvell Technology's long position.

The idea behind CRISPR Therapeutics AG and Marvell Technology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.